ShareSoc Webinar

Sensyne Health

Lord Paul Drayson

Founder and Chief Executive Officer

The webinar will start soon

ShareSoc Webinar

Sensyne Health

Attendee Poll

Presentations at ShareSoc Events

IMPORTANT INFORMATION

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars or other meetings organised or sponsored by ShareSoc. The information given in such meetings is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell, or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research.

Welcome to ShareSoc

- **ShareSoc is a not-for-profit membership organisation**
  - For individual investors, with c 7,000 members
- **We campaign**
  - Government, Regulators,
  - Companies

- **We inform**
  - Investor Webinars, Seminars and Visits, Monthly Newsletters,
  - Blogs, AGM and remuneration reports
- **We educate**
  - Masterclasses, Investor Academy, SIGnet

- **We create networking opportunities**
  - Online Forums, Seminars, SIGnet
- **We save you money**
  - Discounts with Stockopedia, Research Tree etc

- **We improve your investing experience**

ShareSoc Webinar with Sensyne Health

Asking questions



ShareSoc Webinar with Sensyne Health

Upvoting questions





‘Upvoting’ ranks questions by popularity

ShareSoc Webinar with Sensyne Health

- **Stockopedia report**
  - Link included in reminder email
  - Link included in ‘chat’ on the toolbar
- **Copy of the presentation pack**
  - Will be posted on website for access behind the paywall
- **DON’T FORGET TO PROVIDE FEEDBACK!**
  - All ShareSoc members have received an email with the link
  - You will also find the link by clicking on ‘chat’ on the toolbar

ShareSoc Webinar with Sensyne Health

Sensyne Health

Presentation by

Lord Paul Drayson

Founder and Chief Executive Officer

Sensyne Health

The Clinical AI company improving patient care
and accelerating medical research

ShareSoc Webinar
Company Presentation

18 February 2021

Disclaimer

DISCLAIMER

The following disclaimer applies to this Presentation. For the purposes of this disclaimer, **"Presentation"** means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting. The purpose of this Presentation is to provide an overview of the interim financial results of Sensyne Health plc (the **"Company"**) and its subsidiary undertakings (the **"Group"**). The information in this Presentation is not intended to form the basis of any contract.

This Presentation does not constitute an offer or invitation for the sale, issuance or purchase of securities or any businesses or assets described in it, nor does it give or purport to give legal, tax or financial advice. Nothing herein shall be taken as constituting the giving of investment advice or an inducement to enter into investment activity in any jurisdiction and this Presentation is not intended to provide, and must not be taken as, the basis of any decision and should not be considered as an invitation, inducement, solicitation or recommendation to purchase, underwrite, subscribe for or otherwise acquire any securities of the Group. The recipient must make its own independent assessment and such investigations as it deems necessary. Save as set out below, the Presentation has been prepared on the basis of information held by the Group and also from publicly available information. This information, which does not purport to be comprehensive, has not been independently verified by or on behalf of the Group. The Presentation does not constitute an audit or due diligence review and should not be construed as such.

The Company nor any of its subsidiary undertakings or any of such persons' respective directors, officers, employees, affiliates, advisers or agents (their **"Associates"**) accepts any responsibility, obligation or liability whatsoever for, or makes any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of, the information in this Presentation or whether any information has been omitted from the Presentation or as to any other information relating to the Company or the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation, its contents or otherwise arising in connection therewith. Except where otherwise indicated in the Presentation, the information provided therein is based on matters as they exist at the date of preparation of the Presentation and not as of any future date and will be subject to updating, revision, verification and amendment without notice and such information may change materially. Neither the Company nor its subsidiary undertakings, or any of such persons' Associates is under an obligation to update, revise or keep current the information contained in this Presentation to which it relates or to provide the recipient of this Presentation with access to any additional information that may arise in connection with it and any opinions expressed in this Presentation are subject to change without notice. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

To the extent available, the industry and market data contained in this Presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this Presentation.

This Presentation, information and opinions contained in this Presentation and the materials distributed in connection with this Presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The information, statements and opinions contained in this Presentation do not constitute a public offer under any applicable legislation or an offer to sell, or a solicitation of an offer to purchase, any securities in and are not for release, publication or distribution (directly or indirectly) in or into the United States, its territories or possessions , Canada, Japan, Australia or the Republic of South Africa or any other jurisdiction where such distribution or offer is unlawful, except in the United States to a limited number of qualified institutional buyers as defined in Rule 144A under the US Securities Act of 1933, as amended (the **"Securities Act"**). Any securities referred to in this Presentation have not been, and will not be, registered under the Securities Act or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

This Presentation includes statements that are, or may be deemed to be, **"forward-looking statements"**. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "targets", "forecasts", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology; by the forward-looking nature of discussions of strategy, plans or intentions; or by their context. These forward-looking statements include all matters that are not historical facts. They appear in a number of places and include, but are not limited to, statements regarding the Group's intentions, beliefs or current expectations concerning, amongst other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they are based on numerous assumptions regarding the Company's present and future business strategies and future events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and the actual results of operations, financial condition, liquidity, prospects, growth and the development of the industry in which the Group operates, may differ materially from those made in or suggested by the forward-looking statements set out in this Presentation. Past performance of the Company cannot be relied on as a guide to future performance. Forward-looking statements speak only as at the date of this Presentation and the Company and any of its subsidiary undertakings or any of such persons' respective directors, officers, employees, agents, affiliates or advisers expressly disclaims responsibility for the accuracy of the opinions expressed in this Presentation or the underlying assumptions, and any obligations or undertaking to release any update of, or additions or revisions to, any forward-looking statements in this Presentation. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. In addition, even if the results of operations, financial condition and liquidity of the Group, and the development of the industry in which the Group operates, are consistent with the forward-looking statements set out in this Presentation, those results or developments may not be indicative of results or developments in subsequent periods.

Sensyne at a glance

Founded in 2018 | Based in Oxford UK, employing approximately 120 people
London Stock Exchange AIM IPO in 2018 | Generated revenues of £2.3m in HY2021

The global Healthcare AI market is forecast to be worth $36bn by 2025[1]

We supply Clinical AI software for remote patient monitoring ~50% of NHS England Trusts and have access to anonymised data on over 6.8 million NHS patients

We provide Clinical AI services to several of the world's leading pharmaceutical companies

Our work is done in collaboration with our partners

Research partner

Technology partner

US sales & marketing partner

Health system partners

Sensyne Health

Sensyne Health applies clinical artificial intelligence in two large market sectors

Healthcare

Clinical AI Patient Remote Monitoring

GDm-Health™
MagnifEye™
BPm-Health™
CVm-Health™
SEND™
DBm-Health™

SENSE™ Clinical AI Algorithm Engine

Real-time decision making support for healthcare practitioners to improve patient outcomes

SENSE™

Life Sciences

Pharma R&D

Clinical AI-enabled clinical trial optimisation and R&D of new medicines

SENSIGHT™

NHS

Real world dataset of ~6.8m anonymised patient records underpins our offering to Healthcare and Life Science

Sensyne Health

Clinical AI platform and core expertise in fusing medical and data science to generate proprietary software tools

Sensyne's unique partnership with the NHS

NHS

Sensyne has access to a database of ~ 6.8m anonymised patient records from 10 agreements signed with NHS Trusts in England and Scotland since 2018

- Strategic research agreements (SRAs) or data access agreements with NHS Trusts allows Sensyne to analyse anonymised patient data.
- Data includes information on patient encounters, demographics, vital signs, lab values, imaging, structured & unstructured notes
- Enables Sensyne to undertake medical research using Clinical AI to improve pharmaceutical research and development and help deliver better patient care
- Ethical and transparent business model ensures NHS Trusts share in the economic success:
    - Equity: NHS Trusts own ~12.6% of Sensyne
    - IT investment
    - Share in revenues generated using Trust data
- Increasing momentum: 5 data agreements signed with NHS Trusts since Oct 2020



Sensyne Health

Building a world-leading health data platform with industrial scale and depth

- Seek to capitalise on our unique partnership with the NHS and expand anonymised patient dataset to ~12.5 million patients by end of 2022
- Discussions ongoing with NHS Trusts representing an aggregate of ~27 million patient records
- Develop a therapeutically targeted ~5 million patient data set outside of the UK
- Larger data set provides critical mass for Sensyne to target Phase IV trials (including reimbursement)
  - NHS 12.5 million patients represents ~20% of UK population
  - Ex-UK datasets to support regulatory requirements in more jurisdictions including the US

Real-world patient dataset

2.1 million
Achieved 30 April 2019

6.8 million
As at 20 January 2021

Expand NHS dataset
12.5 million
End of 2022 target

Outside UK dataset target
5.0 million
End of 2022 target

17.5 million patients
Combined target for end of 2022

The value of patient data*

Value per data point:

- Disease specific genetic data is higher value
- Highly curated data is more valuable
- Perceived potential of insights from data increases value



* As at IPO in 2018

Sensyne Data Platform for Life Science:
Clinical AI-enabled clinical trial optimisation and R&D



Hospital digital records

Anonymised at source

Sensyne's anonymised patient database

+

Phesi Clinical trial dataset

Phesi

SENSIGHT™

Offer to Life Science

- Synthetic clinical trials
- Testing & validating products
- Market access & reimbursement strategies
- Target identification to support drug discovery

SENSE™

Offer to Healthcare

Life Sciences: Pharma pay Sensyne to analyse real world patient data

Use of real-world anonymised patient data to support pharmaceutical and biotechnology companies research and development activities:

- Optimisation of clinical trial design and execution
- Testing and validating products
- Supporting drug launch and reimbursement strategies
- Target identification to support drug discovery

Clinical trials market expected to grow: $46.8bn in 2019 to $69.9bn by 2027

Five commercial agreements with major pharmaceutical and biotech companies signed since 2019:

Bayer	Roche	Alexion	Bristol Myers Squibb
July 2019 & Oct 2019	**Dec 2019**	**May 2020**	**Oct 2020**
Two agreements worth >£5m	Focus on single disease area	Focus on rare diseases	Undisclosed terms

Business development pipeline supports entering into new commercial agreements during 2021.

Building SENSIGHT™, a world class data platform for Life Science partners

Investing to analyse and process data much more rapidly and cost effectively

Industrialisation	Standardisation	Scale
Grow capacity of real-world patient datasets	Significantly reduce timescales for data access	Revenue growth with economies of scale

SENSIGHT™ Impact on speed of data analysis

Data category answers:	**Now:** weeks	SENSIGHT: Seconds
Clinical AI answers:	**Now:** months	SENSIGHT: Weeks

- Time to build SENSIGHT : Version 1 expected to be ready by Mid-20221
- Leveraging Microsoft technology platform to provide state of the art cyber security and data processing efficiency
- Ability to cope with multiple languages

Sensyne Health

Strategic Collaboration with Phesi, Inc. commenced January 2021

Large curated clinical trial database

- ~13.5 million patient records from ~320,000 global clinical trials since 2007
- Data curated across multiple therapeutic areas, including rare diseases

Strong client base:

Takeda, Incyte, IPSEN, AstraZeneca, mundipharma, Lilly

Phesi

US clinical data company, complementary business development capabilities

ClinSite™, a clinical trial analytics platform

- Allows deployment and development of multiple new product offerings, including synthetic control arms, to the pharmaceutical industry

Seasoned management team

- Experience in clinical trials, data science and business development within healthcare and IT sectors

Key terms

- Initial 5 year term, then auto renewal every 2 years
- Revenue share arrangement
- $10m investment by Sensyne
- Sensyne has 10% equity in Phesi

Combined expertise generates compelling offering to Life Science industry

Phesi

Clinical Trials Database and Analytics Platform

~13.5m patients (clinical trials)

Real World Patient Database and Analytics Platform

~6.8 m patients (NHS)

Sensyne Health

- Synthetic clinical trials & post approval Phase IV trials (including reimbursement)
- Testing and validating products
- Target identification to support drug discovery
- Development of clinical AI algorithms

Clinical AI in clinical trials:
Potential to reduce time, costs and increase clinical trial success rates

The Problem:
High costs and failure rates in the clinical development of new drugs

- **Clinical dev costs per drug: $965 m[1]**
- **4 in 5 drugs fail to progress through Phase 2 and 3 trials to market launch[2]**

Why? Reasons include:

- Flawed study design
- Inappropriate statistical endpoints
- Underpowered study
- Failure to recruit sufficient patients

Potential solution:
Use of real-world patient data and AI to power clinical trials for success

How?

- Optimise clinical trial design upfront
- Develop synthetic control arms as part of clinical trial
- Target higher cost Phase 2 and Phase 3 clinical trials across multiple therapeutic areas

Sensyne seeks to generate commercial returns by partnering with life science companies to optimise their clinical trials

1 https://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/12742/DiMasi-Grabowski-Hansen-RnD-JHE-2016.pdf;sequence=1
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092479/

Sensyne Data Platform for Healthcare:
Providing clinical AI software solutions to global healthcare systems and payers



Hospital digital records

Anonymised at source

Sensyne's anonymised patient database

SENSIGHT™

Offer to Life Science

Offer to Healthcare

SENSE™

- Near real-time clinical decision support
- Algorithms to assist operational planning
- Offer to payers/insurers for population health outcomes



SENSE Clinical Algorithm Engine: Providing real time clinical and operational management support for clinicians and healthcare administrators



- Cloud-based, scalable, and high-performance
- Designed in collaboration with clinicians
- One AI platform, multiple conditions

Algorithms that improve administrative operations and clinical workflow is a growing market that is currently valued at $19.5 billion globally

Syne-COV: Near real-time decision support for COVID-19

SENSE™

Overview of Syne-COV

- Developed in partnership with Chelsea & Westminster NHS Trust
- Predicts risk of ICU admission, mechanical ventilation and mortality

Explainable predictions of patient risk for clinicians



Potential benefits

- Personalised clinical care and early intervention for at-risk patients
- Faster recovery; less time spend in ICU, on ventilators and in hospital
- Improved operational planning (# of ventilators and ICU beds needed)

24 point increase in prediction performance



Heldt et al., medRxiv, 2020
Fletcher et al., medRxiv, 2020
Abu-Jamous et al., medRxiv, 2020

5-fold increase in precision



1 National Early Warning Score (NEWS2)

Sensyne Health

US launch of AI enabled digital therapeutic for gestational diabetes

- Launch in the US of GDm-Health, our remote monitoring software product for diabetes in pregnancy in December 2020
- Over 20% of pregnancies in the US are affected by diabetes annually[1]
- GDm-Health is a direct patient to clinician blood glucose monitoring management system that has been specifically designed for the management of diabetes during pregnancy
- Sale of digital health product supported by agreement with Cognizant
- US launch builds on progress of GDm-Health in the UK

>50

NHS Trusts
using GDm-Health
Across England

>16,000

babies born
to diabetic mothers in the UK cared for by GDM-Health since launch in November 2018



1. International Diabetes Federation: Diabetes Atlas 2019

MagnifEye: An AI powered software product launched in Jan 2021

MagnifEye™



- Initial application of MagnifEye in reading of Lateral Flow Tests (LFT)
- Results in <2 seconds, via the cloud, with very high accuracy and the ability to read beyond the human visible spectrum via a smartphone
- Potential application in other diagnostic tests or medical imaging
- Enables big data analytics and disease surveillance across large populations
- Developed in response to Covid-19 pandemic ,with input from our key partners Microsoft and Cognizant



MagnifEye: Transforming smartphones into lateral flow test readers

MagnifEye commercial licensing agreement with Excalibur

Exclusive licence agreement for use of MagnifEye AI technology by Excalibur Health Systems in lateral flow tests (LFTs) signed Feb 2021

MagnifEye™

MagnifEye to be integrated into Excalibur's proprietary LFT for public and private sectors:

- Sensyne receive royalty each time MagnifEye is used to read a lateral flow test
- Minimum guaranteed royalty of £4.8m for first two years of agreement
- Excalibur current LFT manufacturing capacity is ~3 million tests per day (~1.1 billion per year)

EXCALIBUR Healthcare Services

Excalibur COVID-19 antigen LFT out-performed other competing LFTs on speed, sensitivity and reliability:

- MHRA approved for mass population in symptomatic and asymptomatic people
- Currently being marketed in across the UK and Europe

Lateral flow tests market worth

~$6.5 billion

and growing



Potential application across other diagnostic LFTs in development, including for serology and cancer

Sensyne Health

Key Financials and Share Information

Key financial and share price information

Key Items	
AIM Share Price (16 Feb 2021)	175.5 pence
Issued share capital outstanding (16 Feb 2021)	159.1 million
Current market cap (16 Feb 2021)	£279.2 million
Revenues (six months ended 31 October 2020)	£2.3 million
Cash (31 October 2020)	£18.6 million
Pro forma cash balance (31 Oct 2020)*	£36.4 million
Debt (31 October 2020)	Nil

Ticker: SENS

* Pro forma figure includes net proceeds of ~£17.8m received after completion of fundraise and Phesi equity investment in January 2021

Major shareholders†

Lord Paul Drayson	23.8%	**Sandgrove**	6.8%
Lansdowne Partners	9.7%	**Gatemore**	6.1%
Acacia Resesrch	9.5%	**Amati**	3.6%
Baillie Gifford	7.9%	**Oxford University Hospitals**	3.5%

† As at 1 February 2021

Future milestones, building on strong recent momentum

- Exceeded our 5m patient record target set at IPO
- Strong and growing reputation with our big pharma clients
- Remote monitoring products launched, including entry into US market
- Strategic collaboration with Phesi to enhance pharma offering
- Licensing agreement with Excalibur for MagnifEye

- Enter new SRAs with NHS Trusts to hit 12.5 million patient target and 5 million international patient target by the end of Dec 2022
- Sign new commercial pharmaceutical contracts, including from Phesi strategic collaboration
- Build first version of SENSIGHT by mid-2021
- Submit first Clinical AI algorithm (SYNE-GDm) for regulatory approval by MHRA
- Submit first Clinical AI algorithm (SYNE-COV) for regulatory approval by FDA
- Revenues: comfortable with market consensus expectations, scaling and industrialisation of data platforms expected to drive future revenue growth

Sensyne Health strategy: Building on momentum to scale the business

FY2019-2021

Prove the Sensyne model in UK

- ✓ Create a data base 5m patients
- ✓ Develop clinical AI software
- ✓ Prove effectiveness of software

FY2021-2023

Scale the business

- Grow data base to 17.5m patients
- Industrialise the software platform
- Offer for synthetic and Phase IV trials
- Reach financial critical mass

Phesi

Apply the Sensyne model in the USA

FY2023-2025

Develop in global markets

Sensyne Health

Designed by clinicians, focused on patients, powered by AI

Contact Us:
investors@sensynehealth.com

Sensyne Health plc, Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE

Appendix

We have access to large and growing data sets of anonymised NHS patient records



6.8 million unique patient records

As at 24 November 2020

29.1 million patient encounters

As at 30 April 2020

SENSIGHT real-world data pharmaceutical R&D platform



Multiple real-world patient data sources

High quality longitudinal, curated, anonymised patient data sets.

Pharma R&D Platform

Receives data in different formats. Harmonises into common format, processes data using AI to answer complex questions.

Results

Answers to client questions and insights relevant to improving pharmaceutical R&D.

Summary of Key Terms

- Sensyne and Phesi Inc. enter exclusive collaboration for the combined offering of clinical trial data and real-world data in synthetic trial arms and clinical decision support tools
- Initial term of 5 years, automatically renews for successive 2 year periods unless terminated
- Sensyne invests $10m in Phesi Inc. Proceeds to be used for specific purposes aimed at enhancing the Phesi offering and activities connected to the strategic collaboration
- Revenue share arrangement
- Sensyne receives 10% equity stake in Phesi Inc.
- Paul Drayson to join Phesi Inc. board

Sensyne Health

Designed by clinicians, focused on patients, powered by AI

Sensyne Health plc, Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE

ShareSoc Webinar

Sensyne Health

Q&A

Reminders

- **Presentation & recording will be on our website**
- **PLEASE PROVIDE FEEDBACK!**
- **Future ShareSoc Events:**
  - **23^{rd} February, 5pm – Ultimate Products (UPGS)**
  - **24^{th} February, 5pm – Cambridge Cognition (COG)**
  - **2^{nd} March, 5pm – Anexo (ANX)**
  - **4^{th} March, 9am – Investing in Asia Masterclass**

Visit www.sharesoc.org/events for more information or to register